Compare BridgeBio Pharma Inc (BBIO) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Salesforce Inc — how do they compare? BridgeBio Pharma Inc trades at $82.09 (market cap $16.46B), while Salesforce Inc trades at $168 (market cap $137.23B). The key difference: Salesforce Inc is far larger — about 8.3× BridgeBio Pharma Inc's market cap, and Salesforce Inc pays a 1.05% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | CRM | |
|---|---|---|
Market Cap | $16.46B | $137.23B |
Sector | Health | Technology |
52-Week High | $90.17 | $270.25 |
52-Week Low | $44.81 | $150.12 |
Enterprise Value | $18.02B | $167.28B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Salesforce (CRM) trades at $168.75, down 1.44% on the day amid a broader tech sell-off. The stock exhibits a neutral technical signal with support near $165 and resistance at $171. Fundamentally, the company shows strong profitability with a 77.64% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights AI-driven growth potential but also reflects market concerns over software stock volatility.
The outlook remains positive given robust earnings beats, high analyst buy ratings (76.84%), and a consensus price target of $235.90, implying significant upside. Key risks include competitive pressures in AI, macroeconomic sensitivity, and the stock's high valuation multiples. Revenue growth and AI monetization are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
